Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio (PASG) stock soars as the company out-licenses gene therapy programs targeting pediatric lysosomal storage diseases to GEMMA Biotherapeutics. Read more here.

Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. Read more here.

Fintel reports that on September 3, 2024, Rodman & Renshaw initiated coverage of Passage Bio (NasdaqGS:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 940.03% Upside As of August ...

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Passage Bio (NASDAQ: PASG) just reported results for the first quarter of 2024. Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -36 cents.

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).